[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Peking University First Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":687},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,155,0,25,[9,45,80,110,135,164,196,225,251,274,304,321,349,377,400,429,456,487,513,541,566,584,614,638,662],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100582532","adjuvant-chemotherapy-for-high-malignant-prostate-cancer-100582532",false,"NCT06864533","Adjuvant Chemotherapy for High Malignant Prostate Cancer","Evaluation of Chemotherapy With Adjuvant Docetaxel After Radiotherapy for Localized High Malignant Prostate Cancer: A Prospective Muti-center Non-Randomized Controlled Trial","PKUFH-GS5","Inclusion Criteria:\n\n1. Histologically confirmed prostate cancer diagnosed by biopsy or surgery with a Gleason score of 9-10 (GG grade 5) or containing Gleason 5 components.\n2. No evidence of distant metastasis confirmed by imaging.\n3. Expected to receive standard radical treatment or postoperative radiotherapy.\n4. Estimated survival time greater than 12 months.\n5. Aged ≥ 18 years.\n6. Karnofsky Performance Status (KPS) ≥ 80.\n7. Adequate blood count: white blood cell ≥ 3.5 × 10\\^9\u002FL, neutrophils ≥ 1.5 × 10\\^9\u002FL, platelets ≥ 100.0 × 10\\^\n\nExclusion Criteria:\n\n1. History of malignant tumors (except those cured for more than 5 years).\n2. Previous abdominal radiation therapy.\n3. Weight loss \\> 10% within the past 6 months.\n4. Pre-existing or concomitant bleeding disorders.\n5. Active infections.\n6. Significant cardiovascular disease (e.g., controlled hypertension, unstable angina, NYHA class ≥ II congestive heart failure, unstable symptomatic arrhythmias, or ≥ II peripheral vascular disease) or any condition deemed intolerable to chemotherapy by the oncology department.","MALE","18 Years","80 Years",{"count":22,"type":23},315,"ESTIMATED","5 Years","OBSERVATIONAL","This study aims to evaluate the efficacy of adjuvant docetaxel chemotherapy following radical radiotherapy in patients with localized high-grade prostate cancer. Eligible participants include those diagnosed with prostate cancer confirmed by biopsy or surgical pathology, with a Gleason score of 9-10 or containing a Gleason 5 component, and no evidence of distant metastasis. Patients will be divided into two groups: the standard treatment group receiving only radical treatment (radiotherapy or surgery), and the standard treatment plus chemotherapy group, receiving four to six cycles of docetaxel chemotherapy after standard treatment. The primary endpoint is Failure-Free Survival (FFS), with secondary endpoints including Biochemical Relapse-Free Survival (BRFS), Metastasis-Free Survival (MFS), Overall Survival (OS), and assessment of adverse events The study aims to better understand the impact of adjuvant chemotherapy on the prognosis of patients with high-risk prostate cancer and determine whether it improves survival outcomes.",[28,29,30,31],"Prostate Cancer","Radiation Therapy","Chemotherapy","Gleason Score","RECRUITING","2026-08-18",{"date":35,"type":36},"2026-08-20","ACTUAL",{"date":38,"type":36},"2019-09-01",{"date":40,"type":23},"2031-09-01",{"name":42,"class":43},"Peking University First Hospital","OTHER",3,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":52,"minAge":53,"maxAge":20,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},"100652525","early-phase-1-68ga-b7-h3-nanobody-immunopet-in-osteosarcoma-100652525","NCT07774533","68Ga-B7-H3 Nanobody ImmunoPET in Osteosarcoma","Clinical Evaluation of a 68Ga-Labeled B7-H3 Nanobody for ImmunoPET Imaging in Patients With Osteosarcoma","Inclusion Criteria:\n\n* Age ≥10 years.\n* Histologically confirmed osteosarcoma.\n* Relapsed or refractory disease following failure of first- or second-line systemic therapy.\n* Ability to understand the study procedures and provide written informed consent (or assent with parental\u002Flegal guardian consent, where applicable).\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding.\n* Severe uncontrolled systemic disease or medical condition that, in the investigator's judgment, may interfere with study participation or image interpretation.\n* Unable to undergo PET\u002FCT examination.\n* Any condition that, in the investigator's judgment, makes the participant unsuitable for enrollment.","ALL","10 Years",{"count":55,"type":23},16,"INTERVENTIONAL",[58],"EARLY_PHASE1","This study aims to evaluate the safety, feasibility, and imaging performance of a novel 68Ga-labeled B7-H3 nanobody for immunoPET imaging in patients with osteosarcoma. Participants with suspected or histologically confirmed osteosarcoma will undergo 68Ga-B7-H3 nanobody PET\u002FCT imaging according to the study protocol. Imaging findings will be compared with conventional imaging and, when available, histopathological results. The study will assess tracer biodistribution, tumor uptake, lesion detectability, and safety to determine the potential clinical value of B7-H3-targeted immunoPET for the diagnosis and evaluation of osteosarcoma.",[61,62],"Osteosarcoma","Osteosarcoma, Recurrent, Refractory",[61,64,65,66,67,68,69,70],"B7-H3","CD276","ImmunoPET","Gallium-68","Nanobody","PET\u002FCT","Molecular Imaging","2026-08-17",{"date":73,"type":36},"2026-08-19",{"date":75,"type":36},"2026-04-01",{"date":77,"type":23},"2026-09-30",{"name":42,"class":43},1,{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":56,"phases":89,"briefSummary":91,"conditions":92,"keywords":98,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":79},"100650942","dexmedetomidine-esketamine-combination-on-depression-and-anxiety-after-laparoscopic-ureteral-reconstruction-100650942","NCT07753772","Dexmedetomidine-Esketamine Combination on Depression and Anxiety After Laparoscopic Ureteral Reconstruction","Perioperative Use of Dexmedetomidine-esketamine Combination on Depression and Anxiety in Patients Undergoing Laparoscopic Ureteral Reconstruction: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged ≥ 18 years;\n2. Diagnosed with ureteral stricture and scheduled for elective laparoscopic ureteral reconstruction under general anesthesia;\n3. Requiring patient-controlled intravenous analgesia after surgery.\n\nExclusion Criteria:\n\n1. Preoperative inability to communicate due to coma, delirium, severe dementia, or language barrier;\n2. History of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis;\n3. Presence of preexisting left ventricular ejection fraction (LVEF) \\\u003C 30%, sick sinus syndrome, severe sinus bradycardia (heart rate \\\u003C 50 beats\u002Fmin), or atrioventricular block above grade II without pacemaker implanted;\n4. Uncontrolled hyperthyroidism or history of pheochromocytoma;\n5. Severe hepatic insufficiency (Child-Pugh Class C), severe renal insufficiency (required preoperative dialysis), or American Society of Anesthesiologists (ASA) physical status classification ≥ IV;\n6. Allergy to dexmedetomidine and\u002For esketamine;\n7. Other conditions deemed unsuitable for study participation by the investigators.",{"count":88,"type":23},658,[90],"PHASE4","Anxiety and depressive symptoms are prevalent in patients undergoing surgical repair for ureteral stricture, driven by chronic pain, renal function concerns, and surgical uncertainty. Dexmedetomidine has anxiolytic and antidepressant effects but may increase bradycardia and hypotension; esketamine provides rapid antidepressant efficacy but may cause psychiatric side effects. Preliminary studies showed that combined use of low-dose dexmedetomidine and esketamine reduced the prevalence of postoperative depressive symptoms without increasing adverse events. This study is designed to test the hypothesis that perioperative use of low-dose dexmedetomidine-esketamine combination may relieve postoperative depressive symptoms and anxiety in patients undergoing laparoscopic ureteral reconstruction.",[93,94,95,96,97],"Ureteral Stricture","Dexmedetomidine","Esketamine","Depressive Symptoms","Anxiety",[99,94,95,100,97],"Laparoscopic ureteral reconstruction","Depressive symptoms","NOT_YET_RECRUITING","2026-08-12",{"date":104,"type":36},"2026-08-14",{"date":106,"type":23},"2026-08",{"date":108,"type":23},"2029-08",{"name":42,"class":43},{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":56,"phases":119,"briefSummary":120,"conditions":121,"keywords":126,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":132,"leadSponsor":134,"locationsCount":79},"100642566","phase-4-fascia-iliaca-block-using-liposomal-bupivacaine-for-analgesia-after-hip-fracture-surgery-100642566","NCT07643792","Fascia Iliaca Block Using Liposomal Bupivacaine for Analgesia After Hip Surgery","Fascia Iliaca Block Using Liposomal Bupivacaine for Analgesia After Hip Surgery: a Randomized Trial","Inclusion Criteria:\n\n* Aged ≥ 18 years.\n* Scheduled to undergo hip replacement surgery.\n* Agree to receive regional nerve block and postoperative patient-controlled intravenous analgesia (PCIA).\n\nExclusion Criteria:\n\n* Inability to communicate due to visual, auditory, language, or other reasons before surgery.\n* Chronic opioid dependence and long-term use of various types of analgesics (for more than 3 months).\n* Severe coagulation abnormalities (International Normalized Ratio \\> 1.7, activated partial thromboplastin time exceeding the normal value by more than 4 seconds, platelet count \\\u003C 80 × 10⁹\u002FL), trauma or infection at the intended puncture site, or severe low back pain.\n* Preoperative severe renal insufficiency (serum creatinine \\> 442 μmol\u002FL or requiring renal replacement therapy), hepatic insufficiency (Child-Pugh class C), or ASA physical status \\> IV.\n* Known allergy to local anesthetics.\n* Any other condition that the investigator or attending physician deems unsuitable for participation in the study.",{"count":118,"type":23},148,[90],"Patients after hip surgery often suffer from severe pain. Inadequate analgesia increases the risk of postoperative delirium, myocardial injury, and other complications. Peripheral nerve block is an important component of multimodal analgesia, but conventional local anesthetics (such as plain bupivacaine) provide only approximately 12 hours of analgesic duration, which is far from covering the most painful 72 hours after surgery. Liposomal bupivacaine has a slow-release property, prolonging the analgesic duration up to 72 hours after a single injection. However, its clinical advantages in hip fracture surgery remain controversial. The investigators suppose that, compared with plain bupivacaine alone, preoperative supra-inguinal fascia iliaca block using liposomal bupivacaine combined with plain bupivacaine can further improve analgesia, decrease opioid consumption, and improve postoperative recovery quality within 72 hours in older patients after hip fracture surgery.",[122,123,124,125],"Fascia Iliaca Block","Liposomal Bupivacaine","Postoperative Pain","Hip Surgery",[122,123,124,127],"Hip surgery","2026-08-08",{"date":130,"type":36},"2026-08-11",{"date":106,"type":23},{"date":133,"type":23},"2028-08",{"name":42,"class":43},{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":146,"conditions":147,"keywords":153,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":79},"100651086","oliceridine-versus-sufentanil-analgesia-for-postoperative-patients-with-obstructive-sleep-apnea-100651086","NCT07753785","Oliceridine Versus Sufentanil Analgesia for Postoperative Patients With Obstructive Sleep Apnea","Effects of Oliceridine Versus Sufentanil Analgesia on Incidence of Postoperative Respiratory Depression in Patients at High-Risk of Obstructive Sleep Apnea: A Prospective Cohort Study","OSA","Inclusion Criteria:\n\n* Aged 18 to 90 years.\n* Diagnosed with obstructive sleep apnea according to polysomnography, or suspected to be at high risk of moderate-to-severe OSA according to the STOP-Bang questionnaire: (1) STOP-Bang score ≥ 5; (2) STOP-Bang score ≥ 3 with serum bicarbonate \\[HCO₃-\\] ≥ 28 mmol\u002FL; (3) STOP score ≥ 2 and male sex; (4) STOP score ≥ 2 and body mass index (BMI) \\> 35 kg\u002Fm²; or (5) STOP score ≥ 2 and neck circumference \\> 40 cm.\n* Scheduled to undergo elective non-cardiac surgery under general anesthesia.\n* Required patient-controlled intravenous analgesia (PCIA) after surgery.\n\nExclusion Criteria:\n\n* Pregnant or lactating women.\n* Scheduled to undergo pulmonary\u002Fthoracic surgery in the current admission;\n* Planning to receive use of epidural analgesia.\n* Preplanned postoperative admission to the intensive care unit (ICU) or requirement for mechanical ventilation.","90 Years",{"count":145,"type":23},851,"Opioids are frequently used for postoperative analgesia but may induce side effects. Opioid-induced respiratory depression is the most dangerous side effect of opioids. Patients with obstructive sleep apnea (OSA) are at higher risk for opioid-induced respiratory depression. Oliceridine is a novel biased μ-opioid receptor agonist that selectively engages the G-protein pathway while reducing β-arrestin recruitment and thus may lower the risk of respiratory depression. The goal of this observational study is to compare the effects of oliceridine versus sufentanil analgesia on the incidence of postoperative respiratory depression in patients with known or suspected OSA in the postoperative period following elective surgery.",[148,149,150,151,152],"Obstructive Sleep Apnea","Postoperative Analgesia","Oliceridine","Sufentanil","Respiratory Depression",[154,155,150,151,156],"Obstructive sleep apnea","Postoperative analgesia","Respiratory depression","2026-08-07",{"date":130,"type":36},{"date":160,"type":23},"2026-09",{"date":162,"type":23},"2029-12",{"name":42,"class":43},{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":171,"sex":52,"minAge":172,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":56,"phases":175,"briefSummary":177,"conditions":178,"keywords":184,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":79},"100649604","perioperative-transcranial-photobiomodulation-and-delayed-neurocognitive-recovery-in-older-patients-100649604","NCT07736092","Perioperative Transcranial Photobiomodulation and Delayed Neurocognitive Recovery in Older Patients","Impact of Perioperative Transcranial Photobiomodulation on Delayed Neurocognitive Recovery in Older Patients After Surgery: a Randomized, Double-blind, Pseudo-modulation-controlled Preliminary Clinical Trial","Inclusion Criteria:\n\n* Aged 65 years or older.\n* Preoperative Mini-Mental State Examination (MMSE) \\\u003C27.\n* Scheduled to undergo non-cardiac, non-neurosurgical surgery under general anesthesia, with an expected surgical duration \\>1 hour.\n* Planned hospital stay of at least 1 day before surgery and at least 2 days after surgery.\n\nExclusion Criteria:\n\n* Communication barriers before surgery due to coma, severe dementia, or language disorders.\n* History of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis, or delirium before surgery.\n* History of brain injury, tumors, or surgery, or intracranial metal implants, or skin or soft tissue injuries on the head or face.\n* History of ischemic or hemorrhagic stroke within 3 months before surgery.\n* An American Society of Anesthesiologists class ≥ IV.\n* Enrolled in other interventional studies.\n* Other conditions deemed unsuitable for study participation.",true,"65 Years",{"count":174,"type":23},130,[176],"NA","Delayed neurocognitive recovery is a common neurocognitive complication in older patients after surgery, especially those with preoperative neurocognitive decline. Transcranial photobiomodulation therapy is a novel neuromodulation technique using transcranial low-power light to modulate brain biological functions. This technique has been used to treat various neurological or psychiatric conditions, including ischemic stroke, traumatic brain injury, and major depression. This study is designed to explore whether using transcranial photobiomodulation therapy during the perioperative period can reduce the incidence of delayed neurocognitive recovery in older patients with pre-existing neurocognitive impairment.",[179,180,181,182,183],"Older Adults","Surgery","Transcranial Photobiomodulation","Delayed Neurocognitive Recovery","Postoperative Delirium",[185,180,186,187,188],"Older adults","Transcranial photobiomodulation","Delayed neurocognitive recovery","Postoperative delirium",{"date":190,"type":36},"2026-08-10",{"date":192,"type":36},"2026-08-05",{"date":194,"type":23},"2027-07",{"name":42,"class":43},{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":56,"phases":205,"briefSummary":208,"conditions":209,"keywords":213,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":79},"100584913","phase-2-comparison-of-atlg-and-atg-for-immune-reconstitution-after-allo-hsct-for-hematologic-malignancy-100584913","NCT06895538","Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy","An Exploratory, Non-Randomized, Controlled Study of the Effect of Rabbit Anti-Human T-Lymphocyte Immunoglobulin (ATLG) Versus Anti-Thymocyte Immunoglobulin (ATG) on Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematologic Diseases","Inclusion Criteria:\n\n* 1）Age ≧18 years, gender is not limited;\n* 2）Histologically or cytologically confirmed diagnosis of malignant hematologic diseases;\n* 3\\) First time undergoing allogeneic hematopoietic stem cell transplantation;\n* 4\\) ECOG score 0-2;\n* 5\\) Hepatic and renal function, cardiopulmonary function meet the following requirements.\n\n  * Serum creatinine ≤ 1.5 ULN; ②Left ventricular ejection fraction ≥ 45%;\n\n    * Blood oxygen saturation \\>91%;\n\n      * Total bilirubin ≤ 2 × ULN; ALT and AST ≤ 3 × ULN; for ALT and AST abnormalities due to disease (e.g., liver infiltrates or bile duct obstruction), in the judgment of the investigator, the values may be adjusted to ≤ 5 × ULN;\n* 6\\) Expected survival is longer than 12 weeks;\n* 7\\) The subjects will voluntarily and strictly comply with the requirements of the study protocol and will sign a written informed consent form.\n\nExclusion Criteria:\n\n* 1\\) Prior treatment with ATG, ALG, or ATLG drugs within the past six months;\n* 2\\) Allergic to any component of ATLG or ATG;\n* 3\\) Bacterial, viral, parasitic, or mycobacterial infections not adequately controlled by treatment, i.e., inability to undergo hematopoietic stem cell transplantation due to severe infection.\n\n  4\\) Women who are pregnant or breastfeeding, or participants of childbearing potential who are unwilling or unable to use effective methods of contraception; 5) Participants enrolled in another clinical trial (of any investigational drug or device) within 30 days prior to the subject's baseline visit. (Subjects enrolled in observational studies are eligible to participate).\n\n  6\\) Any other circumstance that, in the judgment of the investigator, may interfere with the conduct of the clinical trial and the determination of the results of the trial.",{"count":204,"type":23},24,[206,207],"PHASE2","PHASE3","Allogeneic hematopoietic stem cell transplantation is the only curative treatment for malignant hematologic diseases. However, immune rejection is a major limitation in its application. In the \"Beijing Protocol\", the use of granulocyte colony-stimulating factor (G-CSF) in combination with anti-thymocyte globulin (ATG) can achieve \"everyone has a donor\". The use of ATG, however, can interfere with the recovery of immune function after transplantation, increasing the risk of life-threatening complications such as viral infections or graft-versus-host disease. Rabbit anti-human T-lymphocyte immunoglobulin (ATLG) is currently approved for the prevention of organ transplant rejection, which is produced differently from ATG. Previous studies have shown that transplant preconditioning with ATLG is effective in preventing graft-versus-host disease and even reduces the incidence of cytomegalovirus, etc. after transplantation. In this study, we will prospectively apply containing ATLG in a cohort of allogeneic hematopoietic stem cell transplantation for malignant hematologic diseases and dynamically observe the state of immune reconstitution of patients after transplantation. We will also compare it with a matched cohort of conventional combined ATGs during the same period to explore the impact of ATLG on immune reconstitution after transplantation.",[210,211,212],"Leukemia","MDS","Lymphoma",[214,215,216,217],"ATLG","ATG","immune reconstitution","allo-HSCT","2026-08-03",{"date":192,"type":36},{"date":221,"type":36},"2025-05-03",{"date":223,"type":23},"2027-02-28",{"name":42,"class":43},{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":56,"phases":233,"briefSummary":235,"conditions":236,"keywords":240,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":79},"100565397","phase-1-a-phase-i-single-arm-clinical-study-of-donor-nk-cells-infusion-combined-with-low-dose-interleukin-2-in-the-treatment-of-acute-myeloid-leukemia-relapse-after-allogeneic-hematopoietic-stem-cell-transplantation-100565397","NCT06641648","A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined With Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.","Inclusion Criteria:\n\n* Age ≥ 18 years old,;\n* Expected survival period ≥ 3 months;\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2;\n* The diagnosis of AML who received allo-HSCT, and met the following criteria:\n\nA. Diagnostic criteria for relapsed AML: after complete remission (CR), leukemia cells reappeared in peripheral blood or blast cells in bone marrow ≥ 5% (except for other reasons such as bone marrow regeneration after consolidation chemotherapy) or extramedullary leukemia cell infiltration; B. Minimal Residual Disease (MRD) positive only or relapse: Patient is minimal residual disease (MRD) positive, as assessed on bone marrow aspirate (BMA) by Multiparameter Flow Cytometry (MFC) at time of Treatment Eligibility assessment; C. Degree II and above acute graft-versus-host disease did not occur after transplantation; D. Available allogeneic hematopoietic stem cell transplant donors.\n\n-Adequate organ function: A. Liver function: ALT≤3×ULN, AST≤3×ULN, total bilirubin≤2×ULN; B. Coagulation function: international normalized ratio (INR) or activated partial thromboplastin time (APTT) ≤ 1.5×ULN; C. Renal function: serum creatinine≤1.5×ULN or creatinine clearance rate ≥30mL\u002Fmin; D. Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 45%;\n\n* Women of child-bearing potential and all male participants must use effective methods of contraception for at least 12 months after infusion.;\n* Informed Consent\u002FAssent: All subjects must have the ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n* Central nervous system involved;\n* Patients who received the following anti-tumor therapies prior to infusion:\n\nA. Systemic use of hormones within 3 days prior to infusion (except for patients with inhaled corticosteroids); B. Systemic anti-tumor therapy within 2 weeks or within 5 drug half-lives (whichever is shorter); C. Radiotherapy within 4 weeks; D. DLI within 6 weeks; E. Intrathecal injection within 1 week; F. Received CAR-T, CAR-NK or other modified cell therapy within 6 months;\n\n* Any active infection requiring systemic therapy by intravenous infusion within 14 days prior to the first dose of study drug, including: HBV, HCV, HIV, syphilis infection, or active pulmonary tuberculosis.\n* History of hypersensitivity reactions to murine protein-containing products, or macromolecular biopharmaceuticals such as antibodies or cytokines;\n* Patients cannot guarantee effective contraception (condom or contraceptives, etc.) within 1 years after enrollment;\n* Women who are pregnant (urine\u002Fblood pregnancy test positive) or lactating;\n* Suffering from a serious autoimmune disease or immunodeficiency disease;\n* Known alcohol dependence or drug dependence;\n* According to the investigator\\'s judgment, the patient has other unsuitable grouping conditions.",{"count":232,"type":23},12,[234],"PHASE1","This is a single-centre, single-arm, open-label, early clinical study to evaluate the safety, tolerability and preliminary efficacy of donor NK cells injection combined with low-dose interleukin-2 in the treatment of acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT).",[237,238,239],"Acute Myeloid Leukemia (AML)","Acute Myeloid Leukemia (AML) Relapse","NK Cell",[241,242,243,244],"AML","relapse","allogeneic hematopoietic stem cell transplantation.","NK cell",{"date":192,"type":36},{"date":247,"type":36},"2025-11-01",{"date":249,"type":23},"2027-06-30",{"name":42,"class":43},{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":56,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":79},"100648097","phase-2-efficacy-and-safety-of-brentuximab-vedotin-combined-with-lisaftoclax-in-cd30-cutaneous-t-cell-lymphoma-ctcl-100648097","NCT07717580","Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)","A Phase II, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in Patients With CD30-positive Cutaneous T-cell Lymphoma (CTCL)","BV-LISA-CTCL","Inclusion Criteria:\n\n1. Age greater than or equal to 18 years.\n2. Confirmed diagnosis of mycosis fungoides (MF) or primary cutaneous anaplastic large cell lymphoma (pcALCL).\n3. CD30 positive confirmed by skin biopsy (at least 2 lesion biopsies for MF patients, and at least 1 lesion biopsy for pcALCL patients). CD30 positivity is defined as greater than or equal to 10% of target lymphocytes showing CD30 membrane, cytoplasmic, and\u002For Golgi-like staining, with a staining intensity higher than the background staining of the corresponding negative control.\n4. Prior treatment requirements:\n\n   * pcALCL: Must have received ≥ 1 prior systemic therapy or radiotherapy.\n   * MF: Must have received ≥ 1 prior systemic therapy.\n   * Note: Patients must be chemotherapy-naïve.\n5. Eastern Cooperative Oncology Group (ECOG) performance status score of less than or equal to 2.\n6. Adequate hepatic, renal, and hematopoietic function.\n7. Females of childbearing potential must be willing to use highly effective methods of contraception during the study and for 6 months after the last dose of study drug; or must be postmenopausal for greater than or equal to 1 year, or surgically sterile.\n8. Males, even if surgically sterilized (i.e., post-vasectomy), must agree to use highly effective methods of contraception during the study and for 6 months after the last dose of study drug.\n9. No cognitive or communication barriers; capable of understanding and willing to sign a written informed consent form (ICF), and willing to comply with the study visits and procedures.\n10. Good venous access for required blood sampling.\n\nExclusion Criteria:\n\n1. Concomitant diagnosis of systemic anaplastic large cell lymphoma (sALCL), other non-Hodgkin lymphomas (except lymphomatoid papulosis), Sézary syndrome, or stage B2 disease.\n2. Active central nervous system (CNS) involvement of lymphoma.\n3. Prior treatment with chemotherapy, allogeneic or autologous stem cell transplantation.\n4. Prior treatment with brentuximab vedotin or any B-cell lymphoma 2 (BCL-2) inhibitors.\n5. Receipt of corticosteroids for cutaneous T-cell lymphoma (CTCL) or skin-directed therapies within 3 weeks prior to the first dose of study drug.\n6. Receipt of antibody-directed therapy, immunoglobulin therapy, or other monoclonal antibodies within 12 weeks prior to the first dose of study drug.\n7. History of other primary malignancies not in complete remission for greater than or equal to 3 years (exceptions: adequately treated carcinoma in situ of the cervix, non-melanoma skin cancer, squamous intraepithelial lesions, or localized prostate cancer with no evidence of recurrence based on prostate-specific antigen (PSA) levels).\n8. Presence of severe organ dysfunction or history of major organ diseases, including:\n\n   * Cardiac: Left ventricular ejection fraction (LVEF) less than 50%; unstable angina; acute myocardial infarction within the past 6 months; New York Heart Association (NYHA) class III-IV congestive heart failure; clinically significant arrhythmias.\n   * Renal: Creatinine clearance ≤ 50 mL\u002Fmin.\n   * Hepatic: Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase \\> 3 × Upper Limit of Normal (ULN), or Total Bilirubin \\> 1.5 × ULN.\n9. Active liver or biliary disease (exceptions: Gilbert's syndrome, asymptomatic gallstones, liver involvement by lymphoma, or stable chronic liver disease assessed by the investigator).\n10. History of severe cerebrovascular disease within the past 6 months, or current presence of symptomatic\u002Fsequelae cerebrovascular events.\n11. History of pancreatitis or high-risk factors for pancreatitis.\n12. Uncontrolled systemic bacterial, fungal, viral, or other severe infections.\n13. Positive test for Human Immunodeficiency Virus (HIV) or Hepatitis B virus (positive HBsAg or HBcAb).\n14. Known hypersensitivity to recombinant proteins, murine proteins, or any excipients of the study drugs.\n15. Female patients who are pregnant, lactating, or planning to become pregnant within 6 months.\n16. Presence of severe concurrent medical\u002Fpsychiatric conditions that may compromise patient safety or compliance, or interfere with informed consent, study participation, or interpretation of results.\n17. Any other conditions that, in the opinion of the investigator, make the patient unsuitable for study participation.",{"count":260,"type":23},46,[206],"This is a prospective, single-center, open-label, randomized, controlled phase II clinical trial. The main purpose of this study is to evaluate the efficacy and safety of combining brentuximab vedotin (an anti-CD30 antibody-drug conjugate, ADC) with lisaftoclax (APG-2575, a novel B-cell lymphoma 2 (BCL-2) inhibitor) in patients with CD30-positive cutaneous T-cell lymphoma (CTCL), specifically including mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (pcALCL).\n\nPrevious studies suggest that the overexpression of the anti-apoptotic protein BCL-2 may contribute to brentuximab vedotin resistance in CTCL. Researchers hypothesize that adding a highly selective BCL-2 inhibitor (lisaftoclax) can reverse this drug resistance, enhance tumor cell apoptosis, and improve clinical outcomes.\n\nIn this study, approximately 46 eligible patients will be randomly assigned in a 1:1 ratio to one of two treatment arms:\n\nMonotherapy arm (control): Patients will receive brentuximab vedotin intravenously at a dose of 1.8 mg\u002Fkg every 3 weeks for a total of 16 cycles.\n\nCombination arm (experimental): Patients will receive the same brentuximab vedotin regimen. Additionally, starting from the 6th cycle, patients will receive oral lisaftoclax. To mitigate the risk of tumor lysis syndrome (TLS), a daily dose ramp-up will be implemented in the first cycle of lisaftoclax. Subsequently, lisaftoclax will be administered at a targeted dose of 600 mg daily on days 1 to 10 of each 21-day cycle, for a total of 9 combination cycles.\n\nThe primary endpoint of the study is the objective response rate (ORR) evaluated at the end of the 16 cycles. Secondary endpoints include the improvement of skin lesions (evaluated by modified severity-weighted assessment tool (mSWAT) score), pruritus relief (visual analog scale (VAS) score), and the incidence of adverse events (AEs). Independent, blinded assessors will be utilized to evaluate the clinical responses to reduce bias.",[264,265],"Cutaneous T-Cell Lymphoma\u002FMycosis Fungoides","Primary Cutaneous Anaplastic Large Cell Lymphoma","2026-07-21",{"date":268,"type":36},"2026-07-23",{"date":270,"type":23},"2026-07-31",{"date":272,"type":23},"2028-12-30",{"name":42,"class":43},{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":56,"phases":284,"briefSummary":285,"conditions":286,"keywords":289,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":79},"100648273","phase-2-neoadjuvant-disitamab-vedotin-toripalimab-and-radiotherapy-for-high-risk-utuc--luxus071--100648273","NCT07720921","Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )","Efficacy and Safety of Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk Upper Tract Urothelial Carcinoma: A Single-arm, Open Label, Prospective Cohort Study","LUXUS0701","Inclusion Criteria:\n\n* Age ≥18 years, male or female.\n* Imaging evaluation before treatment excludes distant organ metastasis or other concurrent malignancy and suggests resectable high-risk UTUC.\n* Completed pathological biopsy with a clear pathological diagnosis : including puncture biopsy, ureteroscopy and urine cytology, at least one of which is clearly diagnosed as uroepithelial carcinoma, which may include no more than 50% or more proportion of squamous, adenoid, sarcomatoid differentiation and other special differentiation types;\n* High-risk features, including muscle-invasive disease, high-grade tumor, multifocal disease, tumor diameter ≥2 cm, hydronephrosis, or regional lymph node involvement.\n* HER2 expression by immunohistochemistry 1+ to 3+; PD-L1 expression not restricted.\n* Have the willingness to undergo radical surgical treatment and perioperative adjuvant treatment, have good compliance, and be able to co-operate with the treatment and follow-up plan specified by the clinician;\n* Postoperative life expectancy of at least 6 months; ECOG score ≤ 2.\n\nExclusion Criteria:\n\n* Distant metastases or other malignant neoplastic diseases combined with other malignant neoplasms in the same period had been detected at the time of surgery, or the present was a progression after palliative resection of previous epithelial carcinoma of the urothelium;\n* History of pelvic and abdominal radiotherapy; history of inflammatory bowel disease; history of systemic chemotherapy;\n* Pregnant women or breastfeeding women; or women of childbearing potential who are not using reliable contraception;\n* The presence of active infections in those with pre-existing or coexisting haemorrhagic disorders\n* clinically significant cardiac disease (e.g., hypertension controlled with medications, unstable angina, New York Heart Association (NYHA) class ≥II congestive heart failure, unstable symptomatic arrhythmias, or class ≥II peripheral vascular disease);\n* Psychological, familial, and social factors leading to lack of informed consent.",{"count":283,"type":23},20,[206],"This is an open-label, single-arm, single-cohort, prospective clinical study evaluating neoadjuvant antibody-drug conjugate therapy combined with immunotherapy and sequential radiotherapy followed by radical surgery in patients with high-risk upper tract urothelial carcinoma (UTUC). Eligible patients will receive neoadjuvant disitamab vedotin (RC48) plus toripalimab, followed by response-guided neoadjuvant radiotherapy and radical nephroureterectomy with bladder cuff excision. The study will assess the safety, feasibility, and preliminary antitumor activity of this multimodal neoadjuvant strategy, with pathological complete response rate as the primary endpoint.",[287,288],"Urothelial Carcinoma of the Renal Pelvis and Ureter","Neoadjuvant Therapy",[290,291,292,293,294,295],"UTUC","neoadjuvant radiotherapy","neoadjuvant immunotherapy","neoadjuvant Antibody-Drug Conjugate","prospective cohort","disitamab vedotin","2026-07-17",{"date":298,"type":36},"2026-07-22",{"date":300,"type":23},"2026-08-01",{"date":302,"type":23},"2029-08-01",{"name":42,"class":43},{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":310,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":311,"conditions":312,"keywords":313,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":319,"leadSponsor":320,"locationsCount":4},"100647420","radioactive-counts-from-psma-petct-targeted-biopsy-specimens-for-real-time-diagnosis-of-prostate-cancer-a-prospective-study-100647420","NCT07709403","Radioactive Counts From PSMA PET\u002FCT-Targeted Biopsy Specimens for Real-time Diagnosis of Prostate Cancer: A Prospective Study","Inclusion Criteria:\n\n* Age 18-80 years;\n* Meeting clinical indications for prostate biopsy (serum PSA persistently \\>4 ng\u002FmL, and at least one lesion with PI-RADS ≥ 3 on magnetic resonance imaging \\[MRI\\]);\n* At least one suspicious lesion detected on PSMA PET\u002FCT;\n* No prior prostate biopsy\n\nExclusion Criteria:\n\n* Prior chemotherapy, pelvic radiotherapy, or androgen deprivation therapy (ADT) for prostate cancer;\n* Prior prostate surgery (transurethral resection of the prostate, etc.);\n* Any contraindications to prostate biopsy, such as active urinary tract infection or indwelling urinary catheter;\n* Biopsy core data with failed gamma spectrometer measurement due to technical reasons.",{"count":283,"type":23},"This study aims to establish the diagnostic threshold and efficacy of radioactive counts (CPM) from biopsy specimens in distinguishing cancer-containing from non-cancer-containing cores, using prostate biopsy pathology as the gold standard. On this basis, we quantitatively analyze the correlations between CPM and both tumor ISUP grade and tumor length, thereby inversely calibrating the pathological significance of PSMA PET\u002FCT imaging signals. Furthermore, we seek to preliminarily define a reference range of imaging signal intensity sufficient to safely obviate the need for biopsy, thereby providing direct pathological evidence to advance non-invasive, biopsy-free diagnosis of prostate cancer.",[28],[314],"Prostate cancer; PSMA PET\u002FCT; Radioactive counts; Targeted biopsy","2026-07-13",{"date":317,"type":36},"2026-07-16",{"date":300,"type":23},{"date":249,"type":23},{"name":42,"class":43},{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":12,"sex":328,"minAge":329,"maxAge":330,"enrollmentInfo":331,"targetDuration":4,"studyType":56,"phases":333,"briefSummary":334,"conditions":335,"keywords":337,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":4},"100646476","phase-4-combined-misoprostol-and-cervical-balloon-vs-misoprostol-alone-for-induction-on-the-first-day-in-primiparas-100646476","NCT07690007","Combined Misoprostol and Cervical Balloon vs Misoprostol Alone for Induction on the First Day in Primiparas","Efficacy of Intravaginal Misoprostol Combined With Cervical Balloon Versus Misoprostol Alone for Induction of Labor on the First Day in Primiparous Women: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 20-45 years at delivery\n* Singleton pregnancy\n* Primiparous\n* Cephalic presentation\n* Cervical Bishop score ≤ 5\n* No history of stillbirth\n\nExclusion Criteria:\n\n* Multiple pregnancy\n* Contraindications to vaginal delivery\n* Mental disorders (depression or anxiety)\n* Preterm labor (\\\u003C 37 weeks)\n* Intrauterine fetal death\n* Previous uterine surgery\n* Premature rupture of membranes\n* Abnormal fetal heart rate tracing","FEMALE","20 Years","45 Years",{"count":332,"type":23},220,[90],"Misoprostol (a prostaglandin E1 analog) is commonly used for cervical ripening and labor induction via vaginal administration. The cervical balloon is another commonly used method that provides mechanical cervical dilation. Both methods are low-cost and widely available. Some meta-analyses have suggested that combined use may shorten the duration of labor, reduce the frequency of tachysystole, and lower NICU admission rates without increasing the risk of cesarean section. However, existing studies are heterogeneous and lack data from Asian populations.\n\nThis study is being done to see whether combining two common methods of labor induction-misoprostol (a medicine placed in the vagina) and a cervical balloon (placed in the cervix) on the first day of induction-can shorten the time from the start of induction to delivery in first-time mothers during pregnancy .\n\nParticipants will be randomly assigned to one of two groups: one group will receive misoprostol alone (standard care) on the first day of induction, and the other group will receive misoprostol plus a cervical balloon on the first day of induction. The main outcome measured is the time from the start of induction to delivery. The study will also look at safety outcomes, including the rate of cesarean section, maternal complications, and newborn outcomes.",[336],"Primiparous Women",[338,339,340],"labor induction","misoprostol","foley balloon catheter","2026-07-07",{"date":343,"type":36},"2026-07-08",{"date":345,"type":23},"2026-06-30",{"date":347,"type":23},"2026-12-31",{"name":42,"class":43},{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":355,"eligibilityCriteria":356,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":172,"enrollmentInfo":357,"targetDuration":4,"studyType":56,"phases":359,"briefSummary":360,"conditions":361,"keywords":363,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":79},"100646433","phase-1-huc-msc-exosomes-for-t2dm---safety--efficacy-100646433","NCT07693036","hUC-MSC-Exosomes for T2DM - Safety & Efficacy","An Exploratory Clinical Study Assessing the Safety and Preliminary Efficacy of Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Adult Type 2 Diabetes Mellitus","HOPE-T2DM","Inclusion Criteria:\n\n1. Age 18-65 years, diagnosed with T2DM for ≥5 years (\\\u003C20 years).\n2. Regular diet and exercise control combined with the following intensive treatment regimens, with screening HbA1c remaining between 7.5% and 9.0% (FBG \\\u003C13.9mmol\u002FL):Stable dose of insulin (basal or premixed) (\\\u003C1.5u\u002Fkg·d) combined with ≥1 oral antidiabetic drug (OAD) (e.g., Metformin, SGLT2i) for ≥3 months; or Insulin combined with a GLP-1RA (maximum tolerated dose, ≤1mg Qw); or GLP-1RA (maximum tolerated dose, ≤1mg Qw) combined with ≥1 OAD for ≥3 months; or Stable dose of ≥3 OADs (must include Metformin) for ≥3 months.\n3. Fasting C-peptide ≥1.0 ng\u002FmL.\n4. Glutamic acid decarboxylase (GAD) antibody and Islet cell antibody (IAA) negative.\n5. Body Mass Index (BMI) 18.5-35 kg\u002Fm ².\n6. Subjects voluntarily participate in the study and sign the informed consent form.\n7. Female subjects of childbearing potential and non-sterilized male subjects must agree to use highly effective contraceptive methods during the study period and for 1 year following the final infusion.\n\nExclusion Criteria:\n\n1. Type 1 diabetes or other specific types of diabetes.\n2. Occurrence of severe hypoglycemia or diabetic ketoacidosis within the past 6 months.\n3. Severe cardiovascular\u002Fcerebrovascular diseases, hepatic or renal insufficiency (e.g., eGFR \\\u003C30 mL\u002Fmin·1.73m²).\n4. Active malignancy, coagulation disorders, immune system diseases.\n5. Pregnant or lactating women.\n6. Individuals with allergic constitution.\n7. Exclusion of subjects currently participating in other clinical trials.\n8. Subjects deemed unsuitable for participation by the investigator.",{"count":358,"type":23},66,[234,206],"The goal of this clinical trial is to Evaluate the Safety and Preliminary Efficacy of Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Adult Type 2 Diabetes Mellitus.",[362],"Type 2 Diabetes Mellitus (T2DM)",[364,365,366,367,368],"MSC-Exosomes","Exosomes","Type 2 Diabetes","Safety","Efficacy","2026-07-03",{"date":371,"type":36},"2026-07-09",{"date":373,"type":36},"2026-06-05",{"date":375,"type":23},"2028-06-08",{"name":42,"class":43},{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":20,"enrollmentInfo":384,"targetDuration":4,"studyType":56,"phases":386,"briefSummary":387,"conditions":388,"keywords":390,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":395,"completionDateStruct":396,"leadSponsor":398,"locationsCount":399},"100646700","phase-4-clinical-study-on-the-effectiveness-of-antibiotics-combined-with-bifidobacterium-quadruple-live-tablets-in-treating-cirrhosis-with-spontaneous-bacterial-peritonitis-and-preventing-recurrence-100646700","NCT07686861","Clinical Study on the Effectiveness of Antibiotics Combined With Bifidobacterium Quadruple Live Tablets in Treating Cirrhosis With Spontaneous Bacterial Peritonitis and Preventing Recurrence","Clinical Study on the Effectiveness of Antibiotics Combined With Bifidobacterium Quadruple Live Tablets in Treating Cirrhosis With Spontaneous Bacterial Peritonitis and Preventing Recurrence-a Randomized, Double-blind, Placebo-controlled Multicenter Clinical Study","Inclusion Criteria:\n\n* Age 18-80, any gender\n* Meets the diagnostic criteria of the Cirrhosis Ascites Diagnosis and Treatment Guidelines (2023 edition), confirmed cirrhosis ascites SBP\n* At least one week before enrollment, no antibiotics or probiotics treatment\n* The patient has some organ function and is expected to live more than a year. Platelets ≥50×10⁹\u002FL, hemoglobin ≥90 g\u002FL (patients with anemia need appropriate treatment) ALT和AST\\\u003C3×ULN Serum creatinine ≤1.5×ULN and creatinine clearance ≥50 mL\u002Fmin\n* Voluntarily sign the informed consent form\n\nExclusion Criteria:\n\n* Patients with severe liver damage (total bilirubin levels more than 5 times the upper limit of normal, mainly with elevated direct bilirubin), hepatorenal syndrome, or hepatic encephalopathy\n* Patients with combined blood and other site (like lungs or urinary system) infections, or those with significant hemodynamic changes, or severe SBP infections\n* Patients with both intrahepatic and extrahepatic malignant tumors, or those with a history of malignant solid tumors or blood cancers\n* Patients with gastrointestinal bleeding or intestinal obstruction who need emergency treatment\n* People who have had serious cardiovascular disease in the past 6 months or currently（ Researchers consider clinically significant myocardial ischemia, myocardial infarction, or unstable angina.Severe arrhythmias that researchers consider clinically significant.Heart failure at NYHA class III-IV.Other acute serious complications that are life-threatening）\n* People with poorly controlled high blood pressure (defined as having a systolic pressure over 160mmHg or a diastolic pressure over 100mmHg despite treatment)\n* Poorly controlled diabetes (defined as blood sugar over 16.8 mmol\u002FL during the screening period despite treatment) or hypoglycemia (blood sugar below 2.8 mmol\u002FL during screening)\n* Select patients who have had esophageal or gastric variceal bleeding within the past 6 months, or those whom the investigator deems at risk of bleeding (if an endoscopy was done within the past 6 months, the results should be collected).\n* People with a history of immune deficiencies, including being HIV positive, having other acquired or congenital immune deficiencies, having idiopathic IgA deficiency, or who have taken systemic steroids (≥10 mg\u002Fday of prednisone equivalent) or immunosuppressive drugs within 14 days before the trial or are expected to need them during the trial.\n* Diagnosed with chronic obstructive pulmonary disease (COPD) and meets the GOLD 2026 Group E criteria\n* Patients who are currently receiving antiviral treatment for hepatitis C virus (HCV) or have received it within 12 months before screening. Patients whose antiviral treatment for hepatitis B virus (HBV) has been less than 12 months before screening.\n* Autoimmune hepatitis patients who received corticosteroid treatment in the past 6 months\n* People who underwent transjugular intrahepatic portosystemic shunt (TIPS) in the past 6 months\n* Patients with liver cirrhosis who have non-bacterial peritonitis caused by reasons other than SBP\n* Patients who are allergic to probiotic ingredients or can't take medicine orally\n* Patients with psychological or mental disorders who are unable to provide an accurate medical history or cooperate\n* Pregnant or breastfeeding women\n* Other researchers think these patients are not suitable",{"count":385,"type":23},360,[90],"This is a prospective, randomized, double-blind, placebo-controlled multicenter clinical study targeting cirrhosis patients with Spontaneous Bacterial Peritonitis(SBP), aiming to evaluate whether adding Bifidobacterium quadruple probiotics can improve infection control rates and reduce SBP recurrence. Meanwhile, by extending the follow-up period into a real-world clinical observation phase, the study will assess whether Bifidobacterium quadruple probiotics can lower SBP recurrence and extend the lifespan of cirrhosis patients. The primary endpoint of the study is the recurrence rate of SBP during the double-blind treatment period. The study plans to enroll 360 patients.",[389],"Cirrhosis With Spontaneous Bacterial Peritonitis",[391,392],"Bifidobacterium quadruple live tablets","Cirrhosis with spontaneous bacterial peritonitis","2026-06-29",{"date":341,"type":36},{"date":270,"type":23},{"date":397,"type":23},"2028-02-28",{"name":42,"class":43},30,{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":406,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":56,"phases":410,"briefSummary":411,"conditions":412,"keywords":415,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":428},"100571617","phase-4-sirolimus-monotherapy-in-the-treatment-of-antiphospholipid-antibody-related-thrombocytopenia-100571617","NCT06722586","Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia","Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia: a Multicenter Randomized, Double Blind, Placebo Controlled, Clinical Trial","SMART","Inclusion Criteria:\n\n* persistent positive of antiphospholipid antibody (either lupus anticoagulant, anti-cardiolipin antibody, or anti-b2GP1 antibody, at least two times with 12 weeks apart)\n* persistent thrombocytopenia (30-100×10\\^9\u002FL, at least for 2 weeks)\n\nEligible concomitant treatment:\n\n* prednisone or equivalent dose less than 10mg per day is allowed, and dose should be stable for more than 2 weeks\n* hydroxychloroquine less than 400mg per day is allowed, and dose should be stable for more than 1 month\n* anti-platelet and\u002For anti-coagulant therapy is allowed, and strength should be the stable for 1 week\n* these following therapies should be discontinued for more than 5 half-lives before the enrollment, including thrombopoietin or thrombopoietin receptor antagonist, intravenous immunoglobulin, immunosuppressants, B cell inhibitors (Belimumab or Talitacicept) and B cell depletion therapy (Rituximab or Obinutuzumab).\n\nExclusion Criteria:\n\n* fulling the criteria of other connective tissue disease other than antiphospholipid syndrome\n* received oral\u002Fintravenous antibiotics within 2 weeks before the enrollment.\n* new onset of thrombosis within 4 weeks before the enrollment.\n* apparent bleeding tendency.\n* life or organ threatening manifestations, includes but not limit to catastrophic antiphospholipid syndrome and thrombotic microangiopathy.\n* liver and renal dysfunction: ALT or AST more than three times of upper limit of normal range; eGFR\\\u003C40mL\u002Fmin\u002F1.73m\\^2\n* hematocytopenia: WBC\\\u003C3.0×10\\^9\u002FL, Hb\\\u003C100g\u002FL.\n* uncontrollable hyperlipidemia: low density lipoprotein cholesterol\\>3.1 mmol\u002FL, triglycerides\\>2.3 mmol\u002FL after lipid lowering therapy.\n* current active infection\n* women in pregnancy and postpartum period",{"count":409,"type":23},84,[90],"The goal of this clinical trial is to evaluate the efficacy and safety of sirolimus in patients with anti-phospholipid antibody-associated thrombocytopenia.\n\nIn the 6-month randomized, double-blind, placebo-controlled phase, participants will receive either sirolimus 1 mg once daily or matching placebo. Participants will be followed at 2 weeks, 1 month, 3 months, and 6 months after enrollment.\n\nParticipants who do not achieve the primary endpoint at 6 months may enter a 3-month open-label extension and receive sirolimus 1.5 mg once daily, with follow-up through month 9.\n\nThe main question is whether sirolimus improves the overall response rate at 6 months compared with placebo.\n\nPrimary outcome:\n\n\\- Overall response rate at 6 months\n\nSecondary outcomes:\n\n* Overall response rate at 1 month and 3 months\n* Complete response rate at 6 months\n* Partial response rate at 6 months\n* Change in anti-phospholipid antibody titers at 6 months\n* Change in oral glucocorticoid dosage at 6 months\n\nExploratory outcomes:\n\n* Proportion and reasons for early discontinuation during the double-blind phase\n* Among participants who do not achieve the primary endpoint at 6 months and enter the open-label extension, overall response rate, complete response rate, partial response rate, and safety outcomes after 3 months of open-label treatment",[413,414],"Antiphospholipid (aPL)-Positive","Thrombocytopaenia",[416,417,418,419,420],"antiphospholipid","thrombocytopaenia","sirolimus","rapamycin","mTOR inhibitor","2026-06-25",{"date":345,"type":36},{"date":424,"type":36},"2025-01-07",{"date":426,"type":23},"2027-12",{"name":42,"class":43},10,{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":12,"sex":52,"minAge":436,"maxAge":20,"enrollmentInfo":437,"targetDuration":4,"studyType":56,"phases":439,"briefSummary":440,"conditions":441,"keywords":445,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":79},"100636786","individualized-transcranial-magnetic-stimulation-in-parkinsonian-disorders-100636786","NCT07570212","Individualized Transcranial Magnetic Stimulation in Parkinsonian Disorders","Exploration of the Efficacy of Individualized Transcranial Magnetic Stimulation in the Treatment of Parkinsonian Disorders","Inclusion Criteria:\n\n1. Diagnostic Criteria Clinically established or clinically probable Parkinson's Disease (PD) according to the 2015 International Parkinson and Movement Disorder Society (MDS) diagnostic criteria; Clinically established or clinically probable Multiple System Atrophy (MSA) according to the 2022 MDS diagnostic criteria; Clinically probable or clinically possible Progressive Supranuclear Palsy (PSP) according to the 2017 MDS diagnostic criteria.\n2. Demographics Aged 30 to 80 years, inclusive; no gender restrictions.\n3. Disease Severity and Staging PD: Modified Hoehn and Yahr (H-Y) stage 2-4; MSA: Unified Multiple System Atrophy Rating Scale (UMSARS) Part IV stage 1-4; PSP: Modified Rankin Scale (mRS) grade 2-4.\n4. Informed Consent and Compliance Ability to understand and comply with the study requirements and provide written informed consent.\n\nExclusion Criteria:\n\n1. Contraindications to TMS Presence of intracranial metallic implants or other foreign bodies, including but not limited to cochlear implants, cardiac pacemakers, or internal metallic\u002Fmagnetic fragments.\n2. Contraindications to EEG and MRI EEG: Known allergy to conductive paste or other EEG-related contraindications. MRI: History of claustrophobia, presence of MRI-incompatible implants, or extensive tattoos.\n3. Concurrent Physical Therapies Currently receiving Transcranial Magnetic Stimulation (TMS) or other therapeutic physical modalities, such as Transcranial Direct Current Stimulation (tDCS).\n4. Unstable Medical Conditions Presence of unstable systemic diseases requiring urgent pharmacological or surgical intervention.\n5. Neurological and Psychiatric History Personal or family history of epilepsy; History of moderate-to-severe psychiatric or psychological disorders; Chronic insomnia or regular use of sedative-hypnotics; Current use of medications that significantly alter central nervous system excitability.","30 Years",{"count":438,"type":23},50,[176],"This clinical trial aims to evaluate whether individualized targeted repetitive transcranial magnetic stimulation (rTMS) can improve motor and non-motor symptoms in patients with parkinsonian disorders. The main question it aims to answer is:\n\n* Does individualized targeted rTMS alleviate symptoms of parkinsonian disorders?\n* Which clinical manifestations of parkinsonian syndromes are responsive to individualized targeted rTMS, and to what degree?\n\nProcedures:\n\n* Preparation (Screening) Participants will undergo clinical assessments, MRI, and EEG before the treatment.\n* Treatment (2 Weeks) Participants will receive a 10-day TMS treatment (once daily, Monday-Friday). Each treatment day takes approximately 3-4 hours. Participants need to keep stable medications and rehabilitation routines during this time.\n* Follow-up (10 Weeks) Participants will undergo follow-up assessments at the end of treatment and 10 weeks after treatment. Assessments include clinical scales, MRI, and EEG.",[442,443,444],"Parkinson's Disease","Multiple System Atrophy","Progressive Supranuclear Palsy",[446,447,448],"parkinsonian disorders","transcranial magnetic stimulation","somato-cognitive action network","2026-06-24",{"date":393,"type":36},{"date":452,"type":36},"2025-12-22",{"date":454,"type":23},"2027-12-22",{"name":42,"class":43},{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":171,"sex":52,"minAge":172,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":56,"phases":465,"briefSummary":466,"conditions":467,"keywords":472,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":486},"100641106","targeted-temperature-management-on-delayed-neurocognitive-recovery-in-older-patients-after-major-cancer-surgery-100641106","NCT07655687","Targeted Temperature Management on Delayed Neurocognitive Recovery in Older Patients After Major Cancer Surgery","Intraoperative Targeted Temperature Management on Delayed Neurocognitive Recovery in Older Patients After Major Cancer Surgery: a Multicenter Randomized Trial","Inclusion Criteria:\n\n1. Age ≥ 65 years.\n2. Planned potentially curative initial cancer surgery with an expected duration of 2 hours or longer under general anesthesia.\n\nExclusion Criteria:\n\n1. Preoperative fever (tympanic temperature ≥ 38℃).\n2. Known or suspected preoperative infection.\n3. Previous schizophrenia, epilepsy, Parkinson's disease, myasthenia gravis, or preexisting delirium.\n4. Inability to communicate due to coma, severe dementia, or hearing or speech impairment.\n5. Critically ill patients, defined as NYHA functional class \\> III or LVEF \\\u003C 30%, Child-Pugh class C, preoperative dialysis dependence, ASA physical status \\> IV, or expected survival \\\u003C 24 hours.\n6. Surgery for breast cancer, intracranial tumors, or rare cancers.\n7. Planned to undergo therapeutic hypothermia.\n8. Body mass index \\> 30 kg\u002Fm² (to facilitate temperature management).\n9. Previous enrollment in this study.\n10. Other conditions deemed unsuitable for study participation.",{"count":464,"type":23},1512,[176],"With aging population, more older patients will receive major surgery for cancer. Older patients are at increased risk of postoperative neurocognitive complications including delayed neurocognitive recovery (dNCR), which is associated with prolonged hospital stay, raised complications, and impaired quality of life. Intraoperative hypothermia occurs in 57.1%-78.6% of patients undergoing major cancer surgery, especially in the elderly. Studies show that intraoperative hypothermia suppresses immune function, interferes with anesthetic metabolism, and delays anesthesia emergence. All these may be correlated with the occurrence of early postoperative dNCR. This study aims to verify whether intraoperative targeted temperature management (target core temperature: 36.8°C) compared with conventional temperature management (core temperature: 35.5°C) can reduce the incidence of dNCR in older patients undergoing major cancer surgery.",[468,469,470,471,182],"Elderly Patients","Cancer Surgery","Hypothermia, Accidental","Targeted Temperature Management",[473,474,475,476,477],"elderly patient","major cancer surgery","intraoperativ hypothermia","targeted temperature management","delayed neurocognitive recovery","2026-06-18",{"date":480,"type":36},"2026-06-23",{"date":482,"type":23},"2026-06",{"date":484,"type":23},"2028-11",{"name":42,"class":43},2,{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":52,"minAge":172,"maxAge":4,"enrollmentInfo":494,"targetDuration":4,"studyType":56,"phases":496,"briefSummary":497,"conditions":498,"keywords":501,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":506,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":512},"100535786","effects-of-intraoperative-targeted-temperature-management-on-incidence-of-postoperative-delirium-and-long-term-survival-100535786","NCT06256354","Effects of Intraoperative Targeted Temperature Management on Incidence of Postoperative Delirium and Long-term Survival","Effects of Intraoperative Targeted Temperature Management on Incidence of Postoperative Delirium and Long-term Survival in Older Patients Having Major Cancer Surgery: A Multicenter Randomized Trial","Inclusion Criteria:\n\n1. Age ≥65 years.\n2. Planned potentially curative initial cancer surgery with an expected duration of 2 hours or longer under general anesthesia.\n\nExclusion Criteria:\n\n1. Preoperative fever (tympanic temperature ≥38℃).\n2. Known or suspected preoperative infection.\n3. Previous history of schizophrenia, epilepsy, Parkinson disease, myasthenia gravis, or delirium.\n4. Unable to communicate due to severe dementia, language barrier, or coma.\n5. Critically ill (Left ventricular ejection fraction \\\u003C30%, Child-Pugh grades C, requirement of renal replacement therapy, American Society of Anesthesiologists physical status\\>IV, or expected survival \\\u003C24 hours).\n6. Scheduled surgery for breast cancer, intracranial tumors, or rare cancers.\n7. Planned to undergo therapeutic hypothermia.\n8. Body mass index \\>30 kg\u002Fm2 (to facilitate thermal management).\n9. Have participated in this study previously.\n10. Any other conditions that are considered unsuitable for study participation.",{"count":495,"type":23},3992,[176],"Intraoperative hypothermia is common in patients having major surgery and the compliance with intraoperative temperature monitoring and management remains poor. Studies suggest that intraoperative hypothermia is an important risk factor of postoperative delirium, which is associated with worse early and long-term outcomes. Furthermore, perioperative hypothermia increases stress responses and provokes immune suppression, which might promote cancer recurrence and metastasis. In a recent trial, targeted temperature management reduced intraoperative hypothermia and emergence delirium. There was also a trend of reduced postoperative delirium, although not statistically significant. This trial is designed to test the hypothesis that intraoperative targeted temperature management may reduce postoperative delirium and improves progression-free survival in older patients recovering from major cancer surgery.",[469,499,471,183,500],"Intraoperative Hypothermia","Long-term Survivors",[502,503,504,188,505],"Cancer surgery","Intraoperative hypothermia","Targeted temperature management","Long-term survival",{"date":480,"type":36},{"date":508,"type":36},"2024-05-29",{"date":510,"type":23},"2032-06",{"name":42,"class":43},36,{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":171,"sex":52,"minAge":19,"maxAge":20,"enrollmentInfo":520,"targetDuration":4,"studyType":56,"phases":521,"briefSummary":522,"conditions":523,"keywords":526,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":538,"leadSponsor":540,"locationsCount":79},"100642057","phase-1-gprc5d-targeted-petct-imaging-in-plasma-cell-disorders-100642057","NCT07660939","GPRC5D Targeted PET\u002FCT Imaging in Plasma Cell Disorders","A Single-Center, Phase I, Single-Arm Prospective Interventional Study of GPRC5D-Targeted PET\u002FCT Imaging in Patients With Multiple Myeloma and Other Plasma Cell Disorders","Inclusion Criteria:\n\n* Adults with confirmed or suspected plasma cell disorders, including multiple myeloma.\n* Healthy volunteers eligible for PET\u002FCT imaging may also be enrolled.\n* Availability of recent clinical laboratory results within 1 week prior to imaging, when applicable.\n* Ability to undergo PET\u002FCT imaging procedures.\n* Ability to understand the study requirements and provide written informed consent.\n\nExclusion Criteria:\n\n* History of other active malignant tumors, unless considered clinically insignificant by the investigator.\n* Pregnant or breastfeeding women.\n* Inability to understand study procedures or comply with imaging examinations.\n* Any medical or psychiatric condition that, in the investigator's judgment, may interfere with study participation or image interpretation.",{"count":438,"type":23},[234],"This is a prospective, single-center, single-arm Phase I study evaluating GPRC5D-targeted PET\u002FCT imaging in patients with plasma cell disorders, including multiple myeloma.\n\nParticipants will undergo GPRC5D-targeted PET\u002FCT, 18F-FDG PET\u002FCT, and 68Ga-BCMA PET\u002FCT within 5 days whenever feasible for head-to-head comparison of lesion detection and disease assessment.\n\nThe study aims to evaluate the safety, feasibility, biodistribution, and diagnostic performance of GPRC5D-targeted PET\u002FCT and to compare its imaging characteristics with currently available molecular imaging modalities in plasma cell disorders.",[524,525],"Plasma Cell Disorders","Multiple Myeloma (MM)",[527,528,529,530,531,69,532,533],"targeted imaging","molecular imaging","GPRC5D","precise oncology","multiple myeloma","nuclear medicine","precise diagnosis","2026-06-16",{"date":536,"type":36},"2026-06-22",{"date":421,"type":23},{"date":539,"type":23},"2027-05-25",{"name":42,"class":43},{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":547,"eligibilityCriteria":548,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":549,"targetDuration":4,"studyType":56,"phases":551,"briefSummary":552,"conditions":553,"keywords":556,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":560,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":4},"100642007","phase-2-efficacy-and-safety-of-benvitimod-cream-in-cutaneous-t-cell-lymphoma-100642007","NCT07658924","Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell Lymphoma","Evaluation of the Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell Lymphoma","BEST-CTCL","Inclusion Criteria:\n\n* Patients diagnosed with cutaneous T-cell lymphoma (CTCL) \u002F mycosis fungoides (MF) by skin biopsy.\n* Aged 18 years or older.\n* Possess complete baseline clinical data.\n* Good compliance with treatment and willing to attend follow-up visits.\n* Conscious, with no cognitive impairment or communication barriers.\n* Voluntarily participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Pregnant or lactating women, or those planning pregnancy within the next 6 months.\n* Known allergy or hypersensitivity to benvitimod cream or its excipients.\n* Severe ulceration or active infection at the target application sites.\n* Unwilling or unable to sign the informed consent form.",{"count":550,"type":23},35,[206],"Background:\n\nCTCL is a rare type of non-Hodgkin lymphoma that primarily affects the skin, causing red patches, plaques, and severe itching. Currently, topical corticosteroids are commonly used for early-stage disease, but long-term application can cause significant skin side effects such as atrophy. Benvitimod is a novel, non-steroidal aryl hydrocarbon receptor (AhR) agonist. Previous studies suggest it has the potential to inhibit tumor cell proliferation and reduce skin inflammation, providing a promising new targeted therapy for CTCL patients.\n\nStudy Design:\n\nThis is a prospective, single-center, double-blind, placebo-controlled study. To ensure a highly accurate comparison and eliminate individual differences, the study uses an intra-patient (left-right) control design. Approximately 35 patients will be enrolled.\n\nParticipants will have two comparable target lesions selected on opposite sides of their body (e.g., left and right trunk or limbs). They will be randomly assigned to apply benvitimod cream to the lesion on one side and a placebo cream to the matching lesion on the other side. The creams will be applied once daily for up to 24 weeks.\n\nResearchers will evaluate the improvement in skin lesions (using the mSWAT score), reduction in itching (using the VAS score), and closely monitor any adverse events at weeks 2, 4, 8, 16, and 24 to assess both the effectiveness and safety of the treatment.",[554,555],"Cutaneous T-Cell Lymphoma","Mycosis Fungoides (MF)",[557,558,559],"Benvitimod","Tapinarof","Topical Therapy",{"date":536,"type":36},{"date":562,"type":23},"2026-07-01",{"date":564,"type":23},"2027-10-01",{"name":42,"class":43},{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":4,"eligibilityCriteria":572,"healthyVolunteers":12,"sex":52,"minAge":573,"maxAge":4,"enrollmentInfo":574,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":576,"conditions":577,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":579,"startDateStruct":580,"completionDateStruct":581,"leadSponsor":583,"locationsCount":4},"100641837","predicting-peritoneal-ktvurea-based-on-single-exchange-dialysate-effluent-100641837","NCT07659067","Predicting Peritoneal Kt\u002FVurea Based on Single-Exchange Dialysate Effluent","Development and Validation of a Prediction Model for Peritoneal Kt\u002FVurea Using Single-Exchange Dialysate Effluent in Patients Undergoing Peritoneal Dialysis","Inclusion Criteria:\n\nPatients aged ≥14 years who have been receiving PD for at least one month.\n\nExclusion Criteria:\n\n(1) peritonitis or other acute complications (e.g., severe infection or acute heart failure) within 1 month prior to enrollment; (2) spontaneous ascites; (3) inability to complete full collection of all dialysate effluent during the study dialysis day; (4) refusal or inability to provide written informed consent.","14 Years",{"count":575,"type":23},300,"Background:\n\nPeritoneal dialysis (PD) adequacy is routinely evaluated using the urea clearance index (Kt\u002FVurea), a key indicator of small-solute clearance and treatment adequacy. The standard method for calculating peritoneal Kt\u002FVurea requires complete collection of 24-hour dialysate effluent, which is labor-intensive, time-consuming, and prone to errors arising from incomplete collection, inadequate mixing, and inaccurate sampling. Although proportional sampling from each exchange has been shown to yield results comparable to those obtained from complete 24-hour effluent collection, this approach still requires collection of all exchanges throughout the day. Previous studies have suggested that Kt\u002FVurea estimated from a single dialysate exchange may correlate with the standard measurement; however, these investigations were limited by small sample sizes and did not establish predictive equations. Therefore, a practical and accurate alternative for assessing peritoneal Kt\u002FVurea is still lacking.\n\nObjective:\n\nTo develop and validate a prediction model for peritoneal Kt\u002FVurea based on single-exchange dialysate effluent in patients undergoing PD.\n\nMethods:\n\nThis multicenter cross-sectional study will be conducted between 2026 and 2027 across four PD centers in China. Consecutive prevalent patients receiving manual PD will be screened for eligibility. Patients aged ≥14 years who have been receiving PD for at least one month will be included. Exclusion criteria comprise peritonitis or other acute complications within the preceding month, spontaneous ascites, inability to complete full dialysate collection during the study day, and refusal to provide informed consent. Demographic characteristics, primary kidney disease, comorbidities, and PD prescription parameters will be collected. On a designated study day, effluent from each dialysis exchange, 24-hour urine samples, and fasting blood samples will be obtained. The correlations between peritoneal Kt\u002FVurea calculated from individual exchanges and the reference peritoneal Kt\u002FVurea derived from complete 24-hour dialysate collection will be evaluated. Multivariable prediction models incorporating single-exchange effluent measurements and relevant clinical parameters will subsequently be developed and validated. Model performance will be assessed using measures of discrimination, calibration, and agreement with reference Kt\u002FVurea values.\n\nConclusions:\n\nThis study aims to establish and validate a simplified method for estimating peritoneal Kt\u002FVurea using single-exchange dialysate effluent. If validated, the proposed model may substantially reduce the burden associated with 24-hour dialysate collection while maintaining adequate accuracy for routine assessment of PD adequacy.",[578],"Peritoneal Dialysis",{"date":536,"type":36},{"date":482,"type":23},{"date":582,"type":23},"2027-06",{"name":42,"class":43},{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":56,"phases":592,"briefSummary":593,"conditions":594,"keywords":600,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":608,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":613,"locationsCount":79},"100632066","phase-1-68ga-pfd3-pet-imaging-for-the-diagnosis-and-evaluation-of-small-cell-lung-cancer-100632066","NCT07508852","68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer","Targeting Delta-like Ligand 3 (DLL3) With 68Ga-PFD3 PET\u002FCT for the Diagnosis and Assessment of Small Cell Lung Cancer (SCLC)","Inclusion Criteria:\n\n* Adults.\n* Histologically confirmed small cell lung cancer (SCLC).\n* At least one measurable lesion ≥1 cm in diameter (primary tumor, metastatic lesion, or involved lymph node) confirmed by standard imaging modalities.\n* Laboratory tests (complete blood count and biochemical analysis) completed within 4 weeks prior to enrollment.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Breastfeeding.\n* Acute psychiatric disorders.\n* Inability to undergo PET scanning (e.g., due to claustrophobia, weight limits, or other medical contraindications).\n* Inability to complete the study procedures as anticipated.\n* Prior therapy targeting DLL3.",{"count":399,"type":23},[234,206],"This study aims to investigate and evaluate the safety and performance of a novel probe, PFD3, for the diagnosis and assessment of patients with small cell lung cancer (SCLC).",[595,596,597,598,599],"SCLC","SCLC, Extensive Stage","SCLC, Limited Stage","Small Cell Lung Cancer","Small Cell Lung Cancer ( SCLC )",[595,601,69,602,603,604,605,606,607],"small cell lung cancer","PET","DLL3","Delta-like ligand 3","imaging","diagnosis","evaluation",{"date":478,"type":36},{"date":610,"type":36},"2025-10-22",{"date":612,"type":23},"2027-12-31",{"name":42,"class":43},{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":619,"acronym":4,"eligibilityCriteria":620,"healthyVolunteers":171,"sex":52,"minAge":19,"maxAge":20,"enrollmentInfo":621,"targetDuration":4,"studyType":56,"phases":622,"briefSummary":623,"conditions":624,"keywords":628,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":631,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":636,"locationsCount":637},"100617536","phase-2-68ga-bcma-petct-in-multiple-myeloma-100617536","NCT07319897","68Ga-BCMA PET\u002FCT in Multiple Myeloma","A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET\u002FCT for Targeting BCMA Expression in Multiple Myeloma.","Inclusion Criteria:\n\n* patients with suspected or previously diagnosed multiple myeloma (MM) who were scheduled for bone marrow aspiration or tissue biopsy within two weeks, including those undergoing initial diagnostic evaluation or follow-up\u002Fre-evaluation for disease monitoring or relapse;\n* patients with confirmed symptomatic MM;\n* ability to understand and voluntarily sign written informed consent;\n* ability to comply with study procedures;\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2.\n\nExclusion Criteria:\n\n* pregnancy or lactation;\n* inability to comprehend study procedures or cooperate with protocol requirements;\n* any other condition judged by the investigator to potentially interfere with study participation.",{"count":575,"type":23},[206,207],"This is a prospective, multicenter diagnostic imaging study designed to evaluate the diagnostic accuracy and clinical utility of BCMA-targeted positron emission tomography\u002Fcomputed tomography (PET\u002FCT) in patients with multiple myeloma and related plasma cell disorders. The study aims to non-invasively visualize and quantify whole-body BCMA expression and to assess its role in the detection of active disease and disease heterogeneity.",[625,626,627],"Multiple Myeloma","Multiple Myeloma and Malignant Plasma Cell Neoplasms","Multiple Myeloma and Plasma Cell Neoplasm",[531,629,69,606,630],"bcma","multicenter",{"date":536,"type":36},{"date":633,"type":36},"2025-12-25",{"date":635,"type":23},"2027-12-30",{"name":42,"class":43},5,{"id":639,"slug":640,"hasResults":12,"nctId":641,"briefTitle":642,"officialTitle":643,"acronym":4,"eligibilityCriteria":644,"healthyVolunteers":12,"sex":52,"minAge":645,"maxAge":4,"enrollmentInfo":646,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":648,"conditions":649,"keywords":655,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":656,"startDateStruct":657,"completionDateStruct":659,"leadSponsor":660,"locationsCount":661},"100577043","diagnosis-and-allergen-identification-of-perioperative-anaphylaxis-100577043","NCT06793163","Diagnosis and Allergen Identification of Perioperative Anaphylaxis","Diagnosis and Allergen Identification of Perioperative Anaphylaxis: a Multicenter Prospective Cohort Study","Inclusion Criteria:\n\n* Aged 2 years or over;\n* Suspected anaphylaxis in the operating rooms, or history of suspected anaphylaxis in the operating room.\n\nExclusion Criteria:\n\n* Refuse to participate;\n* Other conditions that are considered unsuitable for study participation.","2 Years",{"count":647,"type":23},115,"Perioperative anaphylaxis may lead to fatal respiratory and\u002For circulatory events, yet both clinical diagnosis and management are challenging. Serum tryptase is an indicator that can provide important retrospective diagnostic value for anaphylaxis. Another key point in perioperative anaphylaxis management is to identify the allergens, and thus avoid re-exposure during later perioperative management. Skin testing is an important way to identify allergens.",[650,651,652,653,654],"Perioperative\u002FPostoperative Complications","Anaphylaxis","Tryptase","Allergens","Skin Testing",[650,651,652,653,654],{"date":478,"type":36},{"date":658,"type":36},"2025-01-25",{"date":426,"type":23},{"name":42,"class":43},6,{"id":663,"slug":664,"hasResults":12,"nctId":665,"briefTitle":666,"officialTitle":667,"acronym":4,"eligibilityCriteria":668,"healthyVolunteers":12,"sex":328,"minAge":19,"maxAge":4,"enrollmentInfo":669,"targetDuration":4,"studyType":56,"phases":671,"briefSummary":672,"conditions":673,"keywords":677,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":681,"lastUpdatePostDateStruct":682,"startDateStruct":684,"completionDateStruct":685,"leadSponsor":686,"locationsCount":79},"100642691","phase-4-intranasal-esketamine-dexmedetomidine-combination-and-postpartum-depression-100642691","NCT07639099","Intranasal Esketamine-dexmedetomidine Combination and Postpartum Depression","Impact of Intranasal Esketamine-dexmedetomidine Combination on Postpartum Depression in Parturients With Prenatal Depressive Symptoms: a Randomized, Double-blind, and Placebo-controlled Trial","Inclusion Criteria:\n\n* Pregnant women aged ≥18 years who are preparing for childbirth;\n* Positive prenatal depression screening, defined as a Patient Health Questionnaire-9 (PHQ-9) score ≥5.\n\nExclusion Criteria:\n\n* History of schizophrenia or existence of communication barriers;\n* Severe obstetric complications, including severe preeclampsia, placenta accreta, HELLP syndrome, placenta previa, placental abruption, or ASA physical status classification \\>III;\n* Contraindications to ketamine\u002Fesketamine, including refractory hypertension, severe cardiovascular disease (NYHA class ≥III), or hyperthyroidism;\n* Contraindications to dexmedetomidine, including severe bradycardia (heart rate \\\u003C50 bpm), or second-degree or higher atrioventricular block;\n* Unsuitable for intranasal administration due to nasal cavity diseases (e.g., rhinitis, nasal polyps, or nasal congestion of any cause);\n* Refusal to participate in this study or concurrent participation in another clinical trial.",{"count":670,"type":23},164,[90],"Esketamine has rapid-onset antidepressant effects and may reduce postpartum depression in parturients with prenatal depressive symptoms. However, its adverse neuropsychiatric symptoms limits clinical application. Dexmedetomidine can alleviate these adverse symptoms and has independent antidepressant effect. This randomized, double-blind, placebo-controlled trial is designed to evaluate whether intranasal esketamine combined with dexmedetomidine can reduce the prevalence of postpartum depression in women with prenatal depressive symptoms.",[674,96,95,94,675,676],"Parturients","Intranasal Administration","Postpartum Depression",[674,678,95,94,679,680],"Prenatal depressive symptoms","Intranasal administration","Postpartum depression","2026-06-11",{"date":683,"type":36},"2026-06-15",{"date":482,"type":23},{"date":162,"type":23},{"name":42,"class":43},""]